Versant Ventures
At Versant Ventures, we work with early-stage companies to target the largest market opportunities in the medical devices, healthcare services, healthcare information technology and life sciences industries. We partner with creative and experienced entrepreneurs to help them build successful companies poised to transform existing markets or create brand new ones. Each market segment requires a unique investment strategy rooted in the fundamentals of the market. We approach each category from an experienced perspective that comes from more than 175 years of combined experience as entrepreneurs and senior management executives.
Web site: www.versantventures.com
At Versant Ventures, we work with early-stage companies to target the largest market opportunities in the medical devices, healthcare services, healthcare information technology and life sciences industries. We partner with creative and experienced entrepreneurs to help them build successful companies poised to transform existing markets or create brand new ones. Each market segment requires a unique investment strategy rooted in the fundamentals of the market. We approach each category from an experienced perspective that comes from more than 175 years of combined experience as entrepreneurs and senior management executives.
Web site: www.versantventures.com
Accuitive Medical Ventures
Accuitive Medical Ventures (AMV Partners) is a venture capital organization focused on early to mid-stage investments in highly proprietary emerging medical device and technology companies. The fund is committed to a risk-reduced approach to venture investing, utilizing a proprietary pipeline of potential transactions through unique relationships with the industry's preeminent incubators and VC investors.
Web site: www.amvpartners.com
Accuitive Medical Ventures (AMV Partners) is a venture capital organization focused on early to mid-stage investments in highly proprietary emerging medical device and technology companies. The fund is committed to a risk-reduced approach to venture investing, utilizing a proprietary pipeline of potential transactions through unique relationships with the industry's preeminent incubators and VC investors.
Web site: www.amvpartners.com
Avalon Ventures
Avalon Ventures is a San Diego-based venture capital fund focusing on seed and early stage companies in the wireless technology and life science industries, primarily in San Diego and California. Our current Fund, Avalon Ventures VII, L.P. is $75 million.
Web site: www.Avalon-Ventures.com
Avalon Ventures is a San Diego-based venture capital fund focusing on seed and early stage companies in the wireless technology and life science industries, primarily in San Diego and California. Our current Fund, Avalon Ventures VII, L.P. is $75 million.
Web site: www.Avalon-Ventures.com
Arboretum Ventures
Arboretum Ventures is an early-stage venture capital firm specializing in the healthcare sector. We invest throughout the United States, but with a special interest in the Midwest. More than simply a financial resource, we are a collaborative, value-added investor actively engaging our companies in strategy, operations, recruiting, fundraising, and exit planning. Arboretum aims to transform young companies into mature and thriving businesses that improve patient outcomes and lower the cost of care, thereby generating superior returns for the entrepreneurs and our investors. Founded in 2002 and headquartered in Ann Arbor, Michigan, Arboretum currently manages approximately $170 million in capital.
Web site: www.arboretumvc.com
Arboretum Ventures is an early-stage venture capital firm specializing in the healthcare sector. We invest throughout the United States, but with a special interest in the Midwest. More than simply a financial resource, we are a collaborative, value-added investor actively engaging our companies in strategy, operations, recruiting, fundraising, and exit planning. Arboretum aims to transform young companies into mature and thriving businesses that improve patient outcomes and lower the cost of care, thereby generating superior returns for the entrepreneurs and our investors. Founded in 2002 and headquartered in Ann Arbor, Michigan, Arboretum currently manages approximately $170 million in capital.
Web site: www.arboretumvc.com
Novo
Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo Ventures is recognized as a significant force within life science venture capital. Novo is active in both Europe and North America. The Novo Ventures team consists of six Partners in Copenhagen, one in London and two in San Francisco. With an evergreen structure, Novo A/S annually invests approximately $75 million in venture capital into private life sciences companies, and thus acts at a pace comparable to a traditional $350-400 million fund. Novo A/S is not a corporate strategic fund; the group invests for financial rather than strategic returns. In total Novo A/S has more than $8 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.
Web site: www.novo.dk
Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo Ventures is recognized as a significant force within life science venture capital. Novo is active in both Europe and North America. The Novo Ventures team consists of six Partners in Copenhagen, one in London and two in San Francisco. With an evergreen structure, Novo A/S annually invests approximately $75 million in venture capital into private life sciences companies, and thus acts at a pace comparable to a traditional $350-400 million fund. Novo A/S is not a corporate strategic fund; the group invests for financial rather than strategic returns. In total Novo A/S has more than $8 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.
Web site: www.novo.dk